AbbVie Q1 Earnings Surge 8% on Immunology Drug Sales

AbbVie Inc. reported first-quarter earnings that exceeded analyst expectations, driven by strong sales of its key immunology drugs. The company's adjusted earnings per share (EPS) came in at $2.46, with revenue growing 8% year-over-year to $13.34 billion. This surpassed the consensus estimates of $2.40 per share and $12.92 billion in revenue.

The standout performers were Skyrizi and Rinvoq, with sales surging over 70% and 57% respectively. However, Humira, AbbVie's flagship drug, saw its sales decline by half. Collectively, these three immunology drugs generated $6.26 billion in revenue, accounting for nearly half of AbbVie's total first-quarter sales.

In response to the strong quarterly performance, AbbVie raised its full-year adjusted EPS guidance to a range of $12.09 to $12.29, up from the previous range of $11.99 to $12.19. The company noted that its current outlook is based on the existing trade environment and does not account for any potential changes in trade policy, including the possibility of tariffs on the pharmaceutical industry.

President Trump has previously indicated plans to impose tariffs on the pharmaceutical sector, which had been exempted from the first round of tariffs announced earlier this month. Despite this potential headwind, AbbVie's stock has risen 1.5% since the start of the year and gained nearly 3% in early afternoon trading on Friday.

Looking ahead, AbbVie has committed to investing $10 billion in the United States over the next decade. This investment is part of the company's broader strategy to strengthen its position in the U.S. market and drive long-term growth. The investment will focus on research and development, manufacturing, and other strategic initiatives aimed at enhancing AbbVie's competitive edge.